JP2010502664A - 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体 - Google Patents

代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体 Download PDF

Info

Publication number
JP2010502664A
JP2010502664A JP2009527065A JP2009527065A JP2010502664A JP 2010502664 A JP2010502664 A JP 2010502664A JP 2009527065 A JP2009527065 A JP 2009527065A JP 2009527065 A JP2009527065 A JP 2009527065A JP 2010502664 A JP2010502664 A JP 2010502664A
Authority
JP
Japan
Prior art keywords
chloro
hydroxy
cyclohexyl
pyridin
phenylethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009527065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502664A5 (cg-RX-API-DMAC7.html
Inventor
ラルフ・グラッター
ドナルド・ジョーンズ
ダニエル・ウムブリヒト
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2010502664A publication Critical patent/JP2010502664A/ja
Publication of JP2010502664A5 publication Critical patent/JP2010502664A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009527065A 2006-09-11 2007-09-10 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体 Withdrawn JP2010502664A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06120424 2006-09-11
US86881406P 2006-12-06 2006-12-06
US86880506P 2006-12-06 2006-12-06
US88525507P 2007-01-17 2007-01-17
PCT/EP2007/007873 WO2008031550A2 (en) 2006-09-11 2007-09-10 Nicotinic acid derivatives as modulators of metabotropic glutanate receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013260495A Division JP5860865B2 (ja) 2006-09-11 2013-12-17 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体

Publications (2)

Publication Number Publication Date
JP2010502664A true JP2010502664A (ja) 2010-01-28
JP2010502664A5 JP2010502664A5 (cg-RX-API-DMAC7.html) 2010-10-21

Family

ID=39184158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009527065A Withdrawn JP2010502664A (ja) 2006-09-11 2007-09-10 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
JP2013260495A Expired - Fee Related JP5860865B2 (ja) 2006-09-11 2013-12-17 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013260495A Expired - Fee Related JP5860865B2 (ja) 2006-09-11 2013-12-17 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体

Country Status (9)

Country Link
US (3) US20100041641A1 (cg-RX-API-DMAC7.html)
EP (2) EP2272509A1 (cg-RX-API-DMAC7.html)
JP (2) JP2010502664A (cg-RX-API-DMAC7.html)
KR (1) KR20090061041A (cg-RX-API-DMAC7.html)
AU (1) AU2007296964B2 (cg-RX-API-DMAC7.html)
CA (1) CA2663113A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009002684A (cg-RX-API-DMAC7.html)
RU (1) RU2014104384A (cg-RX-API-DMAC7.html)
WO (1) WO2008031550A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530566A (ja) * 2008-08-12 2011-12-22 ノバルティス アーゲー 4−オキソ−オクタヒドロ−インドール−1−カルボサイリックアシッドメチルエステルとその誘導体の調製方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003913A (es) * 2007-10-12 2010-04-27 Novartis Ag Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
CA2774981A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
US20130274294A1 (en) * 2010-12-20 2013-10-17 David Carcache 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
JP6715239B2 (ja) * 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ.ベー. 置換2−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
JP2005514381A (ja) * 2001-12-04 2005-05-19 ノバルティス アクチエンゲゼルシャフト Mglur5アンタゴニスト活性を有するアセチレン誘導体
WO2005105759A1 (de) * 2004-04-28 2005-11-10 Grünenthal GmbH SUBSTITUIERTE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-d]PYRIMIDIN-2-YL- UND 5, 6, 7, 8-TETRAHYDRO-CHINAZOLIN-2-YL-VERBINDUNGEN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
EP1165084A4 (en) 1999-03-03 2002-05-15 Merck & Co Inc INHIBITORS OF PRENYL PROTEIN TRANSFERASES
CH1196397H1 (de) * 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006519251A (ja) * 2003-03-04 2006-08-24 アデックス ファーマシューティカルズ ソシエテ アノニム mGluR5アンタゴニストとしての新規アミノピリジン誘導体
JP2007509935A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズii
WO2005044266A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
BRPI0620066A2 (pt) * 2005-12-20 2011-11-01 Novartis Ag derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514381A (ja) * 2001-12-04 2005-05-19 ノバルティス アクチエンゲゼルシャフト Mglur5アンタゴニスト活性を有するアセチレン誘導体
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
WO2005105759A1 (de) * 2004-04-28 2005-11-10 Grünenthal GmbH SUBSTITUIERTE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-d]PYRIMIDIN-2-YL- UND 5, 6, 7, 8-TETRAHYDRO-CHINAZOLIN-2-YL-VERBINDUNGEN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530566A (ja) * 2008-08-12 2011-12-22 ノバルティス アーゲー 4−オキソ−オクタヒドロ−インドール−1−カルボサイリックアシッドメチルエステルとその誘導体の調製方法

Also Published As

Publication number Publication date
AU2007296964B2 (en) 2012-05-31
AU2007296964A1 (en) 2008-03-20
EP2069305A2 (en) 2009-06-17
KR20090061041A (ko) 2009-06-15
CA2663113A1 (en) 2008-03-20
JP5860865B2 (ja) 2016-02-16
WO2008031550A2 (en) 2008-03-20
WO2008031550A3 (en) 2008-08-21
MX2009002684A (es) 2009-06-05
JP2014088404A (ja) 2014-05-15
US20140187600A1 (en) 2014-07-03
RU2014104384A (ru) 2015-08-20
EP2272509A1 (en) 2011-01-12
US20100041641A1 (en) 2010-02-18
US20120309742A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
JP5860865B2 (ja) 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
TWI243164B (en) Acylated indanyl amines and their use as pharmaceuticals
RU2266284C2 (ru) N-окиси производных 4-фенилпиридина, лекарственное средство, содержащее их
JP3267635B2 (ja) Cox−2阻害物質としてのインドール化合物
JP3604399B2 (ja) Nos阻害剤として有用な6−フェニルピリジル−2−アミン誘導体
JP5306201B2 (ja) N−(アミノヘテロアリール)−1h−インドール−2−カルボキシアミド誘導体、ならびにその調製および治療的用途
JP2009519986A (ja) 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体
AU6227398A (en) Nicotinamide derivatives
JPH0233705B2 (cg-RX-API-DMAC7.html)
JP2008513505A5 (cg-RX-API-DMAC7.html)
JP2008513505A (ja) 複素環式誘導体およびステアロイル−CoAデサチュラーゼのメディエータとしてのそれらの使用
CN113354651A (zh) 吡唑并[1,5-a]喹唑啉衍生物及其在药物制备中的用途
WO2002055484A1 (en) Biaryl compound, process for producing the same, and agent
JP2014240425A (ja) パーキンソン病処置用代謝型グルタミン酸受容体モジュレーター
WO2004078723A1 (ja) 4-ピリジルアルキルチオ基を置換基として有する新規化合物
EP1885697A2 (en) Soluble epoxide hydrolase inhibitors and methods of using same
JP2020506226A (ja) アミド化合物およびその使用
JP5593380B2 (ja) 11−β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害化合物
WO2002006273A1 (en) Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
RU2127732C1 (ru) Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы
JP2013539775A (ja) N−ピリジン−3−イル又はn−ピラジン−2−イルカルボキサミド類
JP5815874B2 (ja) Hdlコレステロール上昇剤としての3−ピリジンカルボン酸ヒドラジド
JP2014533662A (ja) Crth2受容体拮抗薬としての窒素含有縮合環式化合物
CA3254742A1 (en) NEW HETEROCYCLIC HISTONE DEACETYLASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION INCLUDING IT
JP2008133269A (ja) 1,4−ベンゾチアジン−3−オン骨格又は3,4−ジヒドロキノリン−2−オン骨格を有する新規化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131226

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140214

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140818

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150223

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150618